Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA May Use Panels More Often To Evaluate Emergency Research Protocols

Executive Summary

FDA is questioning whether protocols for emergency research conducted without individual informed consent should be subjected to more public input
Advertisement

Related Content

Hemopure advisory committee
Hemopure advisory committee
Biopure Disclosure Policies To Be Reviewed Under Hemopure SEC Settlement
Biopure Disclosure Policies To Be Reviewed Under Hemopure SEC Settlement
FDA informed consent waivers could eliminate barriers for trials of 12 therapies.
FDA informed consent waivers could eliminate barriers for trials of 12 therapies.
Advertisement
UsernamePublicRestriction

Register

PS047555

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel